In fact in patients with mucosal melanoma and tumor PD-L1 expression ≥ 5% (n = 15), ORR was 53.3% (95% CI: 26.6–78.7%), while in patients with PD-L1 expression < 5% (n = 49)—ORR is 12.2% (95% CI: 4.6–24.8%), and in these patients median PFS with PD-L1 expression ≥ 5% was 12.2 months (95% CI: 3.0 months—not reached), while for PD-L1 expression < 5%—median PFS was < 3 months while the role of tumor PD-L1 expression as a response biomarker was not fully defined [25,39]. The gene discussed is CD274; the disease is neoplasm.